LONGEVERON INC-A (LGVN)
US54303L2034 - Common Stock
Overall LGVN gets a fundamental rating of 2 out of 10. We evaluated LGVN against 588 industry peers in the Biotechnology industry. While LGVN seems to be doing ok healthwise, there are quite some concerns on its profitability. LGVN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
LGVN had negative earnings in the past year.
LGVN had a negative operating cash flow in the past year.
In the past 5 years LGVN always reported negative net income.
In the past 5 years LGVN always reported negative operating cash flow.
1.2 Ratios
LGVN has a worse Return On Assets (-183.94%) than 88.74% of its industry peers.
LGVN's Return On Equity of -329.57% is on the low side compared to the rest of the industry. LGVN is outperformed by 76.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -183.94% | ||
| ROE | -329.57% | ||
| ROIC | N/A |
ROA(3y)-97.5%
ROA(5y)-72.15%
ROE(3y)-155.64%
ROE(5y)-144.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 30.57%, LGVN is in the better half of the industry, outperforming 76.96% of the companies in the same industry.
LGVN's Gross Margin has been stable in the last couple of years.
LGVN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.39%
GM growth 5Y-0.48%
2. Health
2.1 Basic Checks
LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LGVN has less shares outstanding
The number of shares outstanding for LGVN has been reduced compared to 5 years ago.
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
LGVN has an Altman-Z score of -14.71. This is a bad value and indicates that LGVN is not financially healthy and even has some risk of bankruptcy.
LGVN's Altman-Z score of -14.71 is on the low side compared to the rest of the industry. LGVN is outperformed by 82.94% of its industry peers.
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.71 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 1.50 indicates that LGVN should not have too much problems paying its short term obligations.
LGVN has a worse Current ratio (1.50) than 83.28% of its industry peers.
A Quick Ratio of 1.50 indicates that LGVN should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.50, LGVN is doing worse than 81.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
The earnings per share for LGVN have decreased strongly by -813.33% in the last year.
LGVN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.03%.
Measured over the past years, LGVN shows a very negative growth in Revenue. The Revenue has been decreasing by -19.75% on average per year.
EPS 1Y (TTM)-813.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1090.48%
Revenue 1Y (TTM)-42.03%
Revenue growth 3Y-49.88%
Revenue growth 5Y-19.75%
Revenue growth Q2Q-47.5%
3.2 Future
LGVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.82% yearly.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y11.9%
EPS Next 2Y14.51%
EPS Next 3Y18.82%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
LGVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LGVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
LGVN's earnings are expected to grow with 18.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.51%
EPS Next 3Y18.82%
5. Dividend
5.1 Amount
LGVN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LONGEVERON INC-A
NASDAQ:LGVN (5/2/2024, 7:04:31 PM)
After market: 1.7601 -0.05 (-2.76%)1.81
+0.07 (+4.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -183.94% | ||
| ROE | -329.57% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.58% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.5 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-813.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-42.03%
Revenue growth 3Y-49.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y